The topic today is some of the older diabetes treatments. I’ll cover some of the newer agents–jardiance, ozempic, trulicity, and so on–next month. The cost-effectiveness literature covers individual drugs and overall goals such as “intensive glucose control” or “goal of normoglycemia.” Before I get into the details, I will try to...
Read More »